Has Inderjit Anand received payments from drug or device companies?

Yes. Drug and device makers reported $384,346 in general payments to Inderjit Anand across 128 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Inderjit Anand did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Inderjit Anand come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Inderjit Anand

Cardiovascular Disease · Minneapolis, MNNPI 1871514513

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $324,391 of the $384,346 with a category attached, or 84.4%. Boehringer Ingelheim International GmbH accounts for 94.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $218,428 and has fallen 93.8% since, to $13,512 in 2023. Among cardiovascular disease clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$384,346in general payments, 2019–2025

Across 128 payments — averaging $3002.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim International GmbH$363K
Rockwell Medical, Inc.$12K
Boston Scientific$4K
Livanova USA, Inc.$3K
Novartis Pharma AG$2K
Amgen$139

$47,984in research payments, 2019–2025

Across 17 payments — averaging $2822.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boehringer Ingelheim International GmbH$46K
Novartis Pharma AG$2K

What the payments were for

Consulting fees$324,39184%
Travel & lodging$58,70615%
Food & beverage$1,2500%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim International GmbH	113	$363,290
Rockwell Medical, Inc.	1	$12,458
Boston Scientific	3	$3,500
Livanova USA, Inc.	6	$3,000
Novartis Pharma AG	1	$1,960
Amgen	4	$139

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$384,346 in reported general payments places this provider in the 95th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota →

Other cardiovascular disease in Minneapolis

Jeffrey ChambersMinneapolis$3.2M
Markus MeyerMinneapolis$786K
Robert SchwartzMinneapolis$502K
Robert VantasselMinneapolis$493K
Nedaa SkeikMinneapolis$453K
Joao CavalcanteMinneapolis$384K
David HurrellMinneapolis$205K
Yader Sandoval PichardoMinneapolis$157K
Charles HerzogMinneapolis$157K
Tamas AlexyMinneapolis$117K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →